Cambridge-based Ophthalmos, specialist in the design, development and marketing of medical devices for use in ophthalmoscopy, has received Food and Drug Administration (FDA) 510(k) clearance to market its Optyse lens-free ophthalmoscope in the USA.
Direct ophthalmoscopy is an effective, noninvasive technique enabling medical practitioners to view the back of the eye for evidence of abnormalities indicative of serious medical conditions including hypertension, diabetes, cerebral malaria and early signs of brain tumours, as well as eye conditions such as glaucoma and cataracts that can lead to reduction of sight or even blindness.
The lens-free technology eliminates the need to calibrate the ophthalmoscope prior to use, providing an immediate and clear view of the retina.
